Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 4Urothelial Cancer 2Urinary Bladder Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Metastatic Adenocarcinoma of the Pancreas 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 2pemigatinib 1ivosidenib 1infigratinib 1futibatinib 1entrectinib 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Cholangiocarcinoma × Gemcitabine × Clear all
NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡